Publication:
Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review

Thumbnail Image

Date

2017

Journal Title

Journal ISSN

Volume Title

Publisher

Springer Healthcare
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Ousler, George W., David Rimmer, Lisa M. Smith, and Mark B. Abelson. 2017. “Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review.” Ophthalmology and Therapy 6 (2): 263-276. doi:10.1007/s40123-017-0110-x. http://dx.doi.org/10.1007/s40123-017-0110-x.

Research Data

Abstract

The many internal and external factors that contribute to the pathophysiology of dry eye disease (DED) create a difficult milieu for its study and complicate its clinical diagnosis and treatment. The controlled adverse environment (CAE®) model has been developed to minimize the variability that arises from exogenous factors and to exacerbate the signs and symptoms of DED by stressing the ocular surface in a safe, standardized, controlled, and reproducible manner. By integrating sensitive, specific, and clinically relevant endpoints, the CAE has proven to be a unique and adaptable model for both identifying study-specific patient populations with modifiable signs and symptoms, and for tailoring the evaluation of interventions in clinical research studies.

Description

Keywords

Aqueous-deficient dry eye, Clinical trials, Controlled adverse environment, Disease models, Drug screening, Dry eye disease, Efficacy endpoints, Evaporative dry eye, Keratitis, Ocular discomfort, Tear film break up, Tear film deficiency

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories